• Product NameAzilsartan
  • CasNo. 147403-03-0
  • MFC25H20N4O5
  • MW456.458
  • Purity
  • Appearance
  • Packing
  • Contact usInquiry

Product Details

CasNo: 147403-03-0

MF: C25H20N4O5

Buy Reliable Quality Azilsartan,Wholesale 147403-03-0 Fast Shipping

  • Molecular Formula:C25H20N4O5
  • Molecular Weight:456.458
  • Melting Point:188 °C(dec.) 
  • PKA:2.05±0.10(Predicted) 
  • PSA:123.24000 
  • Density:1.42 cm3 
  • LogP:4.19180 

Azilsartan(Cas 147403-03-0) Usage

Description

Azilsartan is in a class of medications called angiotensin II receptor antagonists. It works by blocking the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently.

Uses

Azilsartan is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly.

 

147403-03-0 Relevant articles

Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium

Swain, Debasish,Patel, Prinesh N.,Palaniappan, Ilayaraja,Sahu, Gayatri,Samanthula, Gananadhamu

, p. 1437 - 1447 (2015)

Rationale Azilsartan medoxomil potassium...

Efficacy of azilsartan on left ventricular diastolic dysfunction compared with candesartan: J-TASTE randomized controlled trial

Shin Ito, Hiroyuki Takahama, Masanori Asakura, Yukio Abe, Masayoshi Ajioka, Toshihisa Anzai, Takuo Arikawa, Takaharu Hayashi, Yorihiko Higashino, Shinya Hiramitsu, Noriaki Iwahashi, Chisato Izumi, Kazuo Kimura, Koichiro Kinugawa, Hidetaka Kioka, Young-Jae Lim, Ken Matsuoka, Satoshi Matsuoka, Hirohiko Motoki, Sunao Nakamura, Takafumi Nakayama, Akihiro Nomura, Taishi Sasaoka, Shin Takiuchi, Shigeru Toyoda, Tomoya Ueda, Tetsuya Watanabe, Akira Yamada, Masayoshi Yamamoto, Takashi Sozu & Masafumi Kitakaze

, Scientific Reports volume 13, Article number: 12517 (2023)

In this randomized, open-label trial, we randomly assigned 193 hypertensive patients with HF and LV ejection fraction ≥ 45% to 20 mg of azilsartan (n = 95) or 8 mg of candesartan (n = 98), once daily for 48 weeks. After the initiation of treatment, changes in the doses of the study drugs were permitted based on the patient’s conditions, including blood pressure (median dose at 48 weeks: azilsartan 20.0 mg/day, candesartan 8.0 mg/day).

AZILSARTAN ALKYL ESTER, METHOD FOR PRODUCING AZILSARTAN METHYL ESTER, AND METHOD FOR PRODUCING AZILSARTAN

-

, (2021/04/17)

PROBLEM TO BE SOLVED: To provide azilsar...

Relevant Products